Patents by Inventor Michael D. VanHeyst

Michael D. VanHeyst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds and uses thereof
    Patent number: 12662451
    Abstract: Disclosed herein are certain chemical compounds of Formula (I): that inhibit Werner Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are therefore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same.
    Type: Grant
    Filed: September 5, 2025
    Date of Patent: June 23, 2026
    Assignees: IDEAYA BIOSCIENCES, INC., GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
    Inventors: Edward Brnardic, Kira A. Campbell, Michael P. Demartino, Lara K. Leister, Tessa Lynch-Colameta, James P. Phelan, Michael D. Vanheyst, Ann M. Rowley, Amberly B. Sanford, Hongyi Yu, Brian T. Jones, Joshua P.G. Taygerly, Daniel L. Severance, Jonathon S. Ryan, Muzaffar Alam, Melissa Fleury, Ryan M. Mcfadden, Scott P. Simonovich
  • CHEMICAL COMPOUNDS AND USES THEREOF
    Publication number: 20260015321
    Abstract: Disclosed herein are certain chemical compounds of Formula (I): that inhibit Werner Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are therefore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same.
    Type: Application
    Filed: September 5, 2025
    Publication date: January 15, 2026
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED, IDEAYA BIOSCIENCES, INC.
    Inventors: Edward BRNARDIC, Kira A. CAMPBELL, Michael P. DEMARTINO, Lara K. LEISTER, Tessa LYNCH-COLAMETA, James P. PHELAN, Michael D. VANHEYST, ANN M. ROWLEY, Amberly B. SANFORD, Hongyi YU, Brian T. JONES, Joshua P.G TAYGERLY, Daniel L. SEVERANCE, Jonathon S. RYAN, Muzaffar ALAM, Melissa FLEURY, Ryan M. MCFADDEN, Scott P. SIMONOVICH
  • ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20240246932
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: May 2, 2022
    Publication date: July 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Jason M. Cox, Michael J. Kelly, III, Mark Eric Layton, Hong Liu, Jian Liu, Akshay A. Shah, Michael D. VanHeyst
  • CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20220380338
    Abstract: Novel compounds of structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of Formula I may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 1, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Jason M. Cox, Michael J. Kelly, III, Mark Eric Layton, Hong Liu, Jian Liu, Akshay A. Shah, Michael D. VanHeyst